181 related articles for article (PubMed ID: 20700122)
1. Molecular basis of chemosensitivity of platinum pre-treated ovarian cancer to chemotherapy.
Glaysher S; Gabriel FG; Johnson P; Polak M; Knight LA; Parker K; Poole M; Narayanan A; Cree IA;
Br J Cancer; 2010 Aug; 103(5):656-62. PubMed ID: 20700122
[TBL] [Abstract][Full Text] [Related]
2. The in vitro effect of gefitinib ('Iressa') alone and in combination with cytotoxic chemotherapy on human solid tumours.
Knight LA; Di Nicolantonio F; Whitehouse P; Mercer S; Sharma S; Glaysher S; Johnson P; Cree IA
BMC Cancer; 2004 Nov; 4():83. PubMed ID: 15560844
[TBL] [Abstract][Full Text] [Related]
3. The role of gemcitabine-based doublets in the management of ovarian carcinoma.
Thigpen T
Semin Oncol; 2002 Feb; 29(1 Suppl 1):11-6. PubMed ID: 11840415
[TBL] [Abstract][Full Text] [Related]
4. [Application of ATP-tumor chemosensitivity assay in recurrent epithelial ovarian cancer].
Zhao D; Wu LY; Li XG; Wang XB; Li M; Li YF; Tian HM; Song PP; Liu J; Chang QY; Zhang W
Zhonghua Zhong Liu Za Zhi; 2010 Nov; 32(11):855-8. PubMed ID: 21223693
[TBL] [Abstract][Full Text] [Related]
5. Resistance gene expression determines the in vitro chemosensitivity of non-small cell lung cancer (NSCLC).
Glaysher S; Yiannakis D; Gabriel FG; Johnson P; Polak ME; Knight LA; Goldthorpe Z; Peregrin K; Gyi M; Modi P; Rahamim J; Smith ME; Amer K; Addis B; Poole M; Narayanan A; Gulliford TJ; Andreotti PE; Cree IA
BMC Cancer; 2009 Aug; 9():300. PubMed ID: 19712441
[TBL] [Abstract][Full Text] [Related]
6. Cost Effectiveness Analysis of Different Management Strategies between Best Supportive Care and Second-line Chemotherapy for Platinum-resistant or Refractory Ovarian Cancer.
Luealon P; Khempech N; Vasuratna A; Hanvoravongchai P; Havanond P
Asian Pac J Cancer Prev; 2016; 17(2):799-805. PubMed ID: 26925683
[TBL] [Abstract][Full Text] [Related]
7. Topotecan and gemcitabine in platinum/paclitaxel-resistant ovarian cancer.
Greggi S; Salerno MG; D'Agostino G; Ferrandina G; Lorusso D; Manzione L; Mancuso S; Scambia G
Oncology; 2001; 60(1):19-23. PubMed ID: 11150903
[TBL] [Abstract][Full Text] [Related]
8. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
[TBL] [Abstract][Full Text] [Related]
9. Individualized long-term chemotherapy for recurrent ovarian cancer after failing high-dose treatment.
Breidenbach M; Rein DT; Mallmann P; Kurbacher CM
Anticancer Drugs; 2002 Feb; 13(2):173-6. PubMed ID: 11901311
[TBL] [Abstract][Full Text] [Related]
10. Expression of Bcl-xL in ovarian carcinoma is associated with chemoresistance and recurrent disease.
Williams J; Lucas PC; Griffith KA; Choi M; Fogoros S; Hu YY; Liu JR
Gynecol Oncol; 2005 Feb; 96(2):287-95. PubMed ID: 15661210
[TBL] [Abstract][Full Text] [Related]
11. [Predicting clinical chemo-sensitivity of primary ovarian cancer using adenosine triphosphate-tumor chemosensitivity assay combined with detection of drug resistance genes].
Zhao D; Zhang W; Li XG; Wang XB; Zhang LF; Li M; Li YF; Tian HM; Song PP; Liu J; Chang QY; Wu LY
Zhonghua Fu Chan Ke Za Zhi; 2011 Mar; 46(3):193-8. PubMed ID: 21575453
[TBL] [Abstract][Full Text] [Related]
12. Dose finding study for combination treatment with topotecan and gemcitabine of patients with recurrent ovarian cancer after failure of first-line chemotherapy with Paclitaxel and platinum.
Sehouli J; Stengel D; Oskay G; Blohmer J; Kaubitzsch S; Lichtenegger W;
Onkologie; 2004 Feb; 27(1):58-64. PubMed ID: 15007250
[TBL] [Abstract][Full Text] [Related]
13. Chemoresistance testing of human ovarian cancer cells and its in vitro model.
Brigulová K; Cervinka M; Tošner J; Sedláková I
Toxicol In Vitro; 2010 Dec; 24(8):2108-15. PubMed ID: 20736059
[TBL] [Abstract][Full Text] [Related]
14. In vitro drug sensitivity predicts response and survival after individualized sensitivity-directed chemotherapy in metastatic melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group.
Ugurel S; Schadendorf D; Pföhler C; Neuber K; Thoelke A; Ulrich J; Hauschild A; Spieth K; Kaatz M; Rittgen W; Delorme S; Tilgen W; Reinhold U;
Clin Cancer Res; 2006 Sep; 12(18):5454-63. PubMed ID: 17000680
[TBL] [Abstract][Full Text] [Related]
15. Sequence-dependent synergism between the new generation platinum agent ZD0473 and paclitaxel in cisplatin-sensitive and -resistant human ovarian carcinoma cell lines.
Rogers P; Boxall FE; Allott CP; Stephens TC; Kelland LR
Eur J Cancer; 2002 Aug; 38(12):1653-60. PubMed ID: 12142057
[TBL] [Abstract][Full Text] [Related]
16. A phase II study of topotecan plus gemcitabine in the treatment of patients with relapsed ovarian cancer after failure of first-line chemotherapy.
Sehouli J; Stengel D; Oskay G; Camara O; Hindenburg HJ; Klare P; Blohmer J; Heinrich G; Elling D; Ledwon P; Lichtenegger W;
Ann Oncol; 2002 Nov; 13(11):1749-55. PubMed ID: 12419747
[TBL] [Abstract][Full Text] [Related]
17. Predicting chemosensitivity to gemcitabine and cisplatin based on gene polymorphisms and mRNA expression in non-small-cell lung cancer cells.
Meng X; Wang G; Guan R; Jia X; Gao W; Wu J; Yu J; Liu P; Yu Y; Sun W; Dong H; Fu S
Pharmacogenomics; 2015 Jan; 16(1):23-34. PubMed ID: 25560468
[TBL] [Abstract][Full Text] [Related]
18. Gemcitabine reverses cisplatin resistance: demonstration of activity in platinum- and multidrug-resistant ovarian and peritoneal carcinoma.
Rose PG; Mossbruger K; Fusco N; Smrekar M; Eaton S; Rodriguez M
Gynecol Oncol; 2003 Jan; 88(1):17-21. PubMed ID: 12504621
[TBL] [Abstract][Full Text] [Related]
19. Combination chemotherapy for choroidal melanoma: ex vivo sensitivity to treosulfan with gemcitabine or cytosine arabinoside.
Neale MH; Myatt N; Cree IA; Kurbacher CM; Foss AJ; Hungerford JL; Plowman PN
Br J Cancer; 1999 Mar; 79(9-10):1487-93. PubMed ID: 10188895
[TBL] [Abstract][Full Text] [Related]
20. Pertuzumab Plus Chemotherapy for Platinum-Resistant Ovarian Cancer: Safety Run-in Results of the PENELOPE Trial.
González-Martín A; Pautier P; Mahner S; Rau J; Colombo N; Ottevanger P; Del Campo JM; Selle F; du Bois A; Gadducci A; García Y; Berton-Rigaud D; Marmé F; Ortega E; Martin N; Bastiere-Truchot L; Kiermaier A; Kurzeder C
Int J Gynecol Cancer; 2016 Jun; 26(5):898-905. PubMed ID: 27206218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
